AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
Why Morningstar thinks Anthropic is worth $1.7 trillion
A look at how we arrive at our base-case valuation for the AI lab, along with bull and bear scenarios.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,273.30 | 109.90 | 1.20% |
| CAC 40 | 8,233.30 | 94.30 | 1.16% |
| DAX 40 | 26,267.19 | 446.83 | 1.73% |
| Dow JONES (US) | 52,389.75 | 1,104.02 | 2.15% |
| FTSE 100 | 10,782.87 | 108.93 | 1.02% |
| HKSE | 24,523.08 | 74.13 | 0.30% |
| NASDAQ | 25,253.14 | 673.71 | 2.74% |
| Nikkei 225 | 60,514.91 | 1,739.41 | 2.96% |
| NZX 50 Index | 14,108.94 | 135.32 | 0.97% |
| S&P 500 | 7,549.94 | 173.08 | 2.35% |
| S&P/ASX 200 | 9,136.40 | 106.70 | 1.18% |
| SSE Composite Index | 3,671.93 | 11.14 | 0.30% |